Watch YouTube Webinar Recording

View Presentations Slide Deck

Just weeks prior to the presidential elections, our expert panel explores the potential impacts of the 2024 fall elections on healthcare marketing, specifically diving into AI, advertising tax and data privacy policy. Learn more in our deep-dive conversation with the 2025 environment impact healthcare marketing.

 

[caption id="attachment_5930" align="alignnone" width="309"] Watch YouTube Webinar Recording[/caption]

View Webinar Slide Deck

Learn more about the Compliancy Group's software – the Guard – to handle the burden of compliance in a simple, fast, and affordable way.

As a Preferred Partner, CHC & 4A's members receive 15% off their compliance solution package!

In conjunction with the release of a new 4A’s-CHC exclusive white paper – Navigating the Health Data Privacy Landscape – our speakers traverse the growing evolution of new laws and regulations attempting to regulate “HIPAA-adjacent” healthcare data, driven by the colossal growth of the digital and wellness-focused marketplace.  This webinar share best practices to help agencies employ compliance management processes to reduce agency liability and risk, both for the benefit of themselves and for their clients.

Speakers

Liam Degnan – Senior Solutions Engineer @ Compliancy Group

Jim Potter – Executive Director @ CHC – Moderator

   

[caption id="attachment_5889" align="alignnone" width="721"] Watch Webinar YouTube Recording[/caption]

View Webinar Slide Deck

Join us for a discussion with FDA on their direct-to-consumer prescription drug advertising final rule which becomes effective on May 20th, establishing new standards required for conveying information in a “major statement” relating to the applicable drug’s major side effects and contraindications in a “clear, conspicuous, and neutral manner” (CCN).

Speakers

Suzanna Boyle – Regulatory Council, Office of Medical Policy, OPDP @ U.S. Food and Drug Administration

James Potter – Executive Director @ CHC

CHC Summary on FDA DTC Prescription Drug Advertising Final Rule FDA Education Resources

• FDA Small Entity Compliance Guide
• CCN Final Rule FAQ’s
• Advertising/Labeling Submission Guidance
• OPDP webpage
• APLB webpage

In conjunction with the release of the joint 4A’s and CHC member exclusive white paper – Navigating the Health Data Privacy Landscape – join us for a one-hour webinar as our speakers traverse the growing tangle of new state laws and federal regulations governing the collection and use of consumer health data. Diving deep into legal statute, recent enforcement actions, and informal guidance document interpretations, we will share best practices for compliance to help agencies to employ strategies to stay on the right side of these new laws and regulations, both for the benefit of themselves and for their clients.

Speakers

Alison Pepper – EVP, Government Relations & Sustainability @ 4A’s – Moderator

Amanda Anderson – VP, Government Relations @ 4A’s

Michael Signorelli – Partner @ Venable LLP

Watch our 30-minute on-demand webinar that cover the Federal Trade Commission's (FTC) jurisdiction in the health privacy space and HIPAA-adjacent ad agencies and communications companies, as well as how the FTC prioritizes enforcement actions in the health privacy space.  Gain insights on what the healthcare advertising industry can do better in terms of health privacy and what input from the healthcare marketing community is helpful for the FTC.

Speakers

Elisa Jillson – Senior Attorney @ FTC

James Potter – Executive Director @ CHC

FTC Education Resources

• FTC Privacy Education Resources Landing Page
• The DNA of privacy and the privacy of DNA
• Protecting the privacy of health information: A baker’s dozen takeaways from FTC cases
• Lurking Beneath the Surface: Hidden Impacts of Pixel Tracking
• Health Breach Notification Rule: The Basics for Business
• Complying with the FTC’s Health Breach Notification Rule

 

Watch a  joint CHC and 4A’s webinar discussion about recent developments concerning consumer data privacy laws, and what they might mean for advertising agencies and publishing business practices on digital advertising, analytics, and health/wellness-related personal information that has this year come increasingly under scrutiny and enforcement by federal agencies and new requirements under the new state privacy laws.

Moderator

Jay Carter – CHC Board Chair /EVP Business Development @ AblesonTaylor

Speakers

James Potter – Executive Director @ CHC

Amanda Anderson – VP Government Relations @ 4A's

Michael Signorelli – Partner @ Venable LLP

Download the guidance: U.S. State Privacy Laws: What Agencies Need to Know – that focuses on the obligations these laws may impose upon agencies related to the personal information agencies collect and process, both on behalf of clients and for their own purposes.

At the end of 2022, the Federal Trade Commission (FTC) released its Health Products Compliance Guidance—a blanket overhaul of the 1998 Guidance, Dietary Supplements: An Advertising Guide for Industry. The 2022 Guidance expands its scope to guide advertising practices for “any health-related product,” including dietary supplements, foods, over-the-counter (OTC) drugs, homeopathic products, devices, health equipment, diagnostic tests, and health-related apps” attempts to “correct misunderstandings” and “urban myths” that have circulated about past FTC substantiation standards. Separately, the Federal Drug Administration (FDA) finalized its Drug Products Labeled as Homeopathic guidance document, which explains FDA’s risk-based approach to prioritizing enforcement action for homeopathic drugs that FDA considers to be illegally marketed. 

Speaker

Claudia Lewis, Partner  @ Venable LLP

• What likely pitfalls might bring an FTC enforcement action alleging an unfair or deceptive practice for healthcare companies in light of this new guidance?
• How should stakeholders reevaluate their advertising and marketing materials for health-related products to ensure compliance with FTC standards in light of the 2022 guidance?

Nearly a year into the Biden administration, Dr. Robert Califf has been nominated to return as FDA Commissioner – amidst a continuing pandemic and criticism of recent FDA decisions and messaging. What’s next for the FDA under Dr. Califf’s leadership?

Speaker

Nancy Bradish Myers – President @ Catalyst Healthcare Consulting

Concern is building in Washington over misuse of personal data and risks to privacy. Meanwhile, Virginia just followed California in enacting comprehensive data privacy regulation, and other states are considering their own laws, forcing businesses to deal with different rules in different states.

• What do we need to know about regulations at the state level?
• Is the effort in Congress to craft bipartisan federal regulation still alive? Who are the key players?
• What are the implications of federal action – or inaction – for healthcare marketing, advertising, and communications?

Speaker

Alison Pepper – EVP Government Relations @ 4As